Benefits and harm of paracetamol and ibuprofen in combination for post-operative pain: Pre-planned subgroup analyses of the multicenter, randomized PANSAID trial.
Kasper Højgaard ThyboDaniel Hägi-PedersenJorn WetterslevJørgen B DahlJanus C JakobsenNiels Anker PedersenKarina JakobsenHans Henrik BülowLouise IbsenSøren OvergaardOle MathiesenPublished in: Acta anaesthesiologica Scandinavica (2019)
These pre-planned subgroup analyses did not suggest that patients in the investigated subgroups benefitted differently from a basic non-opioid analgesic regimen consisting of paracetamol and ibuprofen. Further, there was no evidence of subgroup heterogeneity regarding harm and use of ibuprofen. Because of reduced statistical power in subgroup analyses, we cannot exclude clinically relevant subgroup heterogeneity.
Keyphrases
- phase iii
- open label
- double blind
- clinical trial
- chronic pain
- placebo controlled
- phase ii
- end stage renal disease
- pain management
- chronic kidney disease
- ejection fraction
- newly diagnosed
- postoperative pain
- neuropathic pain
- study protocol
- patient reported outcomes
- high resolution
- spinal cord
- anti inflammatory
- mass spectrometry
- patient reported
- high speed